A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition.
Levis, M; Smith, BD; Beran, M; Baer, MR; Erba, HP; Cripe, L; Coutre, S; Advani, A; Perl, A; Devetten, M; Stuart, R; Tallman, MS; Brown, P; Tremmel, L; Small, D
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
47th Annual Meeting of the American-Society-of-Hematology
Conference Start Date
Conference End Date